Katrina Berry was 24 years old when she first started experiencing symptoms of pulmonary arterial hypertension (PAH), a ...

In addition to being diagnosed more frequently in older patients, pulmonary arterial hypertension (PAH) is more frequently ...

ECMO or ventilator use was the most significant predictor of mortality in patients undergoing lung transplant for idiopathic ...

Riociguat is generally safe and effective for PAH patients with coexisting cardiac and metabolic conditions, a trials ...

The Drugs Controller General of India (DCGI) has declared as many as 16 commonly-used medicines as spurious, after they ...

At ERS 2024, experts debated systemic thrombolysis vs mechanical and surgical treatments for high-risk pulmonary embolism, ...

In The Lancet Respiratory Medicine, Olivier Sitbon and colleagues1 present the results of a randomised, phase 2b clinical trial (ELEVATE-2) that compared the safety and efficacy of pulmonary arterial ...

Pulmonary arterial hypertension (PAH), a common complication of systemic sclerosis, carries a very severe prognosis and is one of the leading causes of death in patients who suffer from it.

New data from the single-center, open-label extension EDITA-ON study suggest that early treatment for pulmonary arterial hypertension (PAH) could benefit patients with systemic sclerosis and early ...

Regarded mostly as a lung disease, PAH is often in people with fewer nail fold capillaries, suggesting a disease of the small ...

Babies born with a narrowed blood vessel now have a device specifically designed for them, thanks to research conducted at ...

Jupiter Endovascular, Inc. announced that the first two patients were treated in the SPIRARE I trial of the Vertex pulmonary ...